Highland Capital Management LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 0.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 190,417 shares of the company’s stock after selling 783 shares during the period. Johnson & Johnson makes up 2.0% of Highland Capital Management LLC’s holdings, making the stock its 5th largest position. Highland Capital Management LLC’s holdings in Johnson & Johnson were worth $23,098,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Americafirst Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $101,000. Capital Asset Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $202,000. Terra Nova Asset Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth $243,000. Daiwa SB Investments Ltd. boosted its stake in shares of Johnson & Johnson by 8.4% in the second quarter. Daiwa SB Investments Ltd. now owns 2,970 shares of the company’s stock worth $354,000 after buying an additional 230 shares during the period. Finally, Pure Financial Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the second quarter worth $355,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) traded up 0.47% on Monday, hitting $119.80. 3,657,049 shares of the stock traded hands. The stock has a market cap of $327.76 billion, a P/E ratio of 22.33 and a beta of 0.62. The stock has a 50-day moving average price of $118.85 and a 200 day moving average price of $117.29. Johnson & Johnson has a 12-month low of $94.12 and a 12-month high of $126.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.68 by $0.06. Johnson & Johnson had a net margin of 20.97% and a return on equity of 24.70%. The firm earned $18.50 billion during the quarter, compared to the consensus estimate of $17.98 billion. On average, equities analysts expect that Johnson & Johnson will post $6.69 EPS for the current fiscal year.

A number of equities analysts have commented on JNJ shares. Wells Fargo & Co. reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 11th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 price objective on the stock in a report on Friday, August 5th. Deutsche Bank AG reiterated a “buy” rating and issued a $142.00 price objective on shares of Johnson & Johnson in a report on Friday, August 19th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $124.21 price objective on the stock in a report on Monday, August 22nd. Finally, Leerink Swann reiterated a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $120.19.

In related news, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $125.01, for a total transaction of $366,904.35. Following the completion of the transaction, the chief accounting officer now directly owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the transaction, the vice president now directly owns 157,819 shares of the company’s stock, valued at $19,728,953.19. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.